- aboBoNTA
abobotulinumtoxinA
- AE
adverse event
- APT
all patients treated
- BoNT
botulinum toxin
- BoNTA
botulinum toxin A
- CI
confidence interval
- CP
cerebral palsy
- DB
double-blind
- EOS
end of study
- EW
early withdrawal
- FMQ
Leeds Functional Mobility Questionnaire
- FPS
Faces Pain Scale
- GAS
goal attainment scaling
- GMFCS
Gross Motor Function Classification System
- GMFM
Gross Motor Function Measure
- GMFM-88
88-item Gross Motor Function Measure
- GSC
gastrocnemius-soleus complex
- ICC
intraclass correlation coefficient
- ITC
indirect treatment comparison
- ITT
intention-to-treat (population)
- LLS
lower-limb spasticity
- LS
least squares
- MAS
Modified Ashworth Scale
- OGS
Observational Gait Scale
- onaBoNTA
onabotulinumtoxinA
- PedsQL
Pediatric Quality of Life Inventory
- PGA
Physician’s Global Assessment
- RCT
randomized controlled trial
- SAE
serious adverse event
- SD
standard deviation
- TEAE
treatment-emergent adverse event
- TS
Tardieu Scale
- U
units
- ULS
upper-limb spasticity
- VGA
Leeds Videographic Gait Assessment
- WDAE
withdrawal due to adverse event
Publication Details
Copyright
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. Abbreviations.